Advance developments in life sciences with a strategic financing partner
Financing a better future
Helping your competitive advantage
Access to state-of-the-art scientific equipment and technology is central to the competitive advantage of R&D intensive life science organisations and academia.
For over 20 years, DLL have offered innovative and flexible funding solutions allowing access to the latest scientific equipment and technology. This helps increase the efficiency and quality of R&D, retain the best scientific talent and support the circular economy helping meet sustainability goals.
For entrepreneurial ventures, typically funded by venture capital or the public markets, these funding solutions help preserve precious cash that is then best deployed in value-enhancing R&D.
For large corporations, funding provides an innovative alternative to capital expenditure procurement. It gives the business a fixed budget throughout the term of the agreement terms, along with known cost of ownership through the life of the equipment.
Our customers include
- Biotechnology organisations.
- Large pharmaceutical companies.
- Contract Research Organisations (CROs) and Contract Development and Manufacturing Organisations (CDMOs); and
- Academia and public sector research establishments.
How DLL can help
Makes equipment accessible and affordable
You can access the latest equipment that provides you with the best results, with affordable payments over the term.
Accelerates your research
Increase the efficiency of your research and advance your operation using the latest scientific equipment and technology.
Attracts and retains the best talent
Basing your organisation in cutting edge facilities helps you attract the best talent in a highly competitive industry.
Makes cash go further
Equipment & technology finance allows you to extend your cash runway and keep cash available for value enhancing research and development.
Improves budgeting
Set customised payment terms to match your cashflow, and accurately know what you are paying and when. With fixed and transparent regular payments, you also keep your lines of credit available for other necessary investments.
Disclaimer: The above does not constitute a financing offer. *Always consult your tax advisor. DLL does not provide tax or accounting advice.
Insights from Dr Stephen Franklin
Experienced Life Sciences Executive | Founder and Former CEO | Advisor and Consultant | PhD MBA
Sharing in vibrant life science ecosystems
Alderley Park, the former Astra Zeneca site, is the UK’s largest single site life sciences campus and home to well over a hundred companies, ranging from start-ups that can “rent a bench” through to large contract research....
How innovative financing equips state-of-the-art laboratories and attracts top talent
I often reflect upon my PhD experience as it remains the hardest thing I have ever done. It was a long-time ago, 1989 to 1993 to be precise. Three years in the laboratory and...
The life sciences industry. A growing powerhouse of the UK economy
In May of this year, the UK government announced a £650m package to support economic growth in the life sciences; a sector that employs over 280,000 people and generates £94 billion in annual turnover across the sector for the UK...
“…DLL offered the most straightforward and flexible arrangements for a growth company like Nuclera”
-Jiahao Huang, Chief Financial Officer, Nuclera
Explore more resources
Developing innovative laboratories via equipment funding
In 2022, Curve signed an agreement with Merck & Co., one of the world’s largest pharmaceutical companies. Using their unique technology, Curve will use its technology to screen against five specific therapeutic targets. The research deal being worth up to US$1.7bn, should all five therapeutic programs succeed.
How innovative financing equips state-of-the-art laboratories and attracts top talent
In the second of our regular series discussing challenges facing the UK life sciences industry, Dr Stephen Franklin reflects on his time as a PhD student, how he grappled with (and often lost against), obsolete and overworked equipment.
Supporting growth in life sciences. Laboratory equipment financing enables optimal use of resources
Nuclera, a UK-based biotechnology company, was founded in 2013 by three PhD students studying at the University of Cambridge. Whilst working on their dissertations, they found that the long lead time and high costs associated with protein prototyping created a significant barrier for scientists when it came to their research.
Advancing life sciences with financial solutions
DLL supports research, development and diagnosis with comprehensive finance offerings and industry expertise.